Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.39 |
| ▸ | ITGAL | P20701 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408917 | 1.00 | AR (0.39) | ARITGB2ICAM1ITGALALDH1A1 | |
| SCHEMBL3410767 | 0.84 | MAOB (0.44) | ALDH1A1GPR183 | |
| SCHEMBL3410772 | 0.84 | MAOB (0.44) | ALDH1A1GPR183 | |
| SCHEMBL3407870 | 0.84 | MAOB (0.44) | ALDH1A1GPR183 | |
| SCHEMBL3407865 | 0.84 | MAOB (0.44) | ALDH1A1GPR183 | |
| SCHEMBL3413674 | 0.81 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL3413679 | 0.81 | ALDH1A1 (0.49) | ALDH1A1 | |
| SCHEMBL3413189 | 0.80 | MAPT (0.47) | ALDH1A1GPR183 | |
| SCHEMBL3413194 | 0.80 | MAPT (0.47) | ALDH1A1GPR183 | |
| SCHEMBL692664 | 0.70 | KDM4E (0.50) | ITGB2ICAM1ITGALALDH1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | WYETH (US) | 2010-03-11 | — | — | US | claimed |
| WO-2005090316-A1 | HYDANTOINS HAVING RNase MODULATORY ACTIVITY | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | WYETH (US) | 2005-09-15 | — | — | US | claimed |
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2005090316-A1 | HYDANTOINS HAVING RNase MODULATORY ACTIVITY | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | WYETH (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063118-A1 | Hydantoins Having RNase Modulatory Activity | RNASEH1, RNASE1, RNASEL | AR 2239/4885ITGB2 4836/4885ICAM1 3175/4885 |
| US-20050203156-A1 | Hydantoins having RNase modulatory activity | RNASEH1, RNASE1, RNASEL | AR 2239/4885ITGB2 4836/4885ICAM1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.